Anthropic Revenue Tops OpenAI, Fuels IPO Hype

Anthropic revenue surge put the company ahead of OpenAI in quarterly sales, accelerating IPO speculation and pressuring AI valuations and flows.

August 19, 2026·2 min read
View all news articles
Flat vector of a server stack representing Anthropic revenue momentum on a light graphite-frost gradient with subtle shadow.

KEY TAKEAWAYS

  • Anthropic told investors its annualized revenue run rate hit about $65 billion.
  • Preliminary Q2 sales were roughly $11.5-11.6 billion, over double Q1.
  • Anthropic's Q2 adjusted results showed a small operating profit, contrasting with OpenAI's wider losses.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Anthropic PBC (P-ANTH) revenue has surged, with investor updates showing the company surpassed OpenAI (P-OPEA) in quarterly sales. This shift has accelerated IPO speculation and intensified debate over whether leading AI models can quickly achieve profitability.

Q2 Revenue Growth and Run Rate Comparison

Anthropic, a privately held artificial intelligence company known for its Claude family of large language models, focuses on enterprise customers and safety-oriented research. The company told investors its annualized revenue run rate reached about $65 billion at the end of July 2026. This figure, an extrapolation from recent results rather than an audited full-year total, marks more than a sevenfold increase from roughly $9 billion at the end of 2025 and a rise from about $47 billion in May 2026.

Preliminary second-quarter 2026 revenue at Anthropic was reported around $11.5–11.6 billion, a more than 14-fold year-over-year increase and over double first-quarter sales of roughly $4.7–4.8 billion. This implies sequential growth exceeding 140%. Multiple accounts say Anthropic swung to a small operating profit or positive adjusted operating income in the quarter, partly due to improved computing-resource efficiency. The company’s use of an adjusted profitability measure, including the treatment of stock-based compensation, has not been fully disclosed.

OpenAI reported second-quarter revenue of $6.7 billion, up 18% from $5.7 billion in the first quarter, with an annualized run rate near $40 billion. However, multiple sources say OpenAI’s losses deepened, with one detailed account citing an operating loss including stock-based compensation of about $12.3 billion in Q2, up from roughly $9.3 billion in Q1. This pushed operating margins further into negative territory.

Anthropic’s second-quarter sales exceeded OpenAI’s for the first time, shifting investor focus to whether monetizing higher-quality models can outpace the scale-and-loss business model.

IPO Valuation and Profitability Debate

Reports describe Anthropic as on track for an initial public offering later in 2026, though no S-1 registration statement has been filed. Secondary analyses have suggested an implied IPO valuation near $2 trillion, roughly a 31-times multiple on the run-rate figure. Some investor projections anticipate full-year 2026 revenue between $100 billion and $120 billion, though these estimates are analytical rather than company guidance.

Anthropic’s move toward adjusted operating profitability challenges the expectation that leading AI models must remain large, loss-making platforms. In contrast, OpenAI’s slower sequential growth and widening losses have disappointed some investors and intensified scrutiny ahead of its own anticipated listing.

Underwriters, investors, and executives will be watching whether Anthropic can sustain the revenue momentum behind its lofty valuation and whether OpenAI can narrow losses or clarify a path to profitability before going public.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Estée Lauder Earnings Beat, China Demand Raises Outlook

Estée Lauder Earnings Beat, China Demand Raises Outlook

Estée Lauder earnings beat Q4 estimates and raised fiscal 2027 guidance; premium fragrances and China demand widened margins and spurred trading momentum.

Merck Moderna Melanoma Vaccine Meets Topline Goals

Merck Moderna Melanoma Vaccine Meets Topline Goals

Merck Moderna melanoma vaccine met primary and key secondary endpoints; companies will present data and engage regulators, creating a filing catalyst.

Keysight Q3 Earnings Lift Outlook On AI Demand

Keysight Q3 Earnings Lift Outlook On AI Demand

Keysight Q3 earnings show record revenue as management cites AI data-center demand and lifts Q4 and FY2026 outlook, reinforcing orders momentum.

SK Hynix Buyback Boosts Shareholder Returns

SK Hynix Buyback Boosts Shareholder Returns

SK Hynix buyback follows record AI-driven results and tightens public float, boosting buyback flows and reinforcing investor positioning.

Lowe's Q2 2026 Results: Flat EPS, Trimmed Outlook

Lowe's Q2 2026 Results: Flat EPS, Trimmed Outlook

Lowe's Q2 2026 results show flat EPS and modest comps and updated 2026 guidance to the low end, trimming upside and pressuring investor expectations.

Palantir Q2 2026 Earnings Fuel Valuation Debate

Palantir Q2 2026 Earnings Fuel Valuation Debate

Palantir Q2 2026 earnings showed accelerating AI revenue and raised FY guidance, tightening the valuation debate and trading risk around positioning.